Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01907191 · ClinicalTrials.gov registry record · NA
Ultrasound Guided Local Infiltration Analgesia for Hip Arthroscopy
A NA study, sponsored by Trinity Health Of New England.
- Terminated
- Registry status
- NA
- Development phase
- 23
- Enrollment target
NCT01907191 is a NA study that was terminated before completion, run by Trinity Health Of New England. The registered enrollment target is 23 participants.
The verdict
NCT01907191, a NA study, was terminated before completion, sponsored by Trinity Health Of New England.
- TERMINATED
- Registry status
- NA
- Development phase
- 23 participants
- Enrollment target
Study Summary
This study is being undertaken to compare the pain control using either bupivacaine versus liposomal bupivacaine. Liposomal bupivacaine can potentially provide pain relief lasting up to 72 hours while regular bupivacaine can provide pain relief up to 12 hours
Interventions
- DRUG Bupivacaine
- DRUG liposomal bupivacaine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2013-07 |
| Est. Completion | 2019-01-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01907191
The ClinicalTrials.gov registry entry for NCT01907191 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Trinity Health Of New England, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Bupivacaine is the first listed.
NCT01907191 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01907191 about?
NCT01907191 is a clinical study titled "Ultrasound Guided Local Infiltration Analgesia for Hip Arthroscopy". This study is being undertaken to compare the pain control using either bupivacaine versus liposomal bupivacaine. Liposomal bupivacaine can potentially provide pain relief lasting up to 72 hours while regular bupivacaine can provide pain relief up to 12 hours
What is the current status of trial NCT01907191?
This trial is currently terminated. It is a NA study. The enrollment target is 23 participants. The study started on 2013-07. Estimated completion is 2019-01-30.
What interventions are being tested in trial NCT01907191?
The interventions under investigation include: Bupivacaine (DRUG), liposomal bupivacaine (DRUG).
Who is sponsoring clinical trial NCT01907191?
This trial is sponsored by Trinity Health Of New England, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.